Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma is developing an oral inhibitor of SARS-CoV-2 Mpro (3CL protease), and a new oral antiviral drug candidate for influenza, which targets the influenza cap-dependent endonuclease and has shown potency in cell based assays against drug resistant viruses.

In cancer, we are developing a novel, proprietary multi-kinase CDK4/6 inhibitor, narazaciclib, for refractory endometrial and potentially other cancers. Narazaciclib targets pathways involved in the development of resistance to this class of drugs.

Traws Pharma is committed to delivering novel compounds for unmet medical needs using state-of-the-art drug development technology and accelerated clinical trial strategies. With a focus on product safety and a commitment to patients in need or that are specifically vulnerable, we build solutions for important medical challenges, aiming to alleviate the burden of viral infections and cancer.